Suraksha Diagnostic Ltd. · NSE:SURAKSHA
Suraksha Diagnostic — H1 FY25 Earnings Presentation
29 slides from Suraksha Diagnostic's earnings presentation, Dec 21, 2024
Slide 1: Revised Investor Presentation filing letter to exchanges
Date: 21 December 2024 To The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block Dalal Street Bandra -Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai- 400 051 Scrip Code: 544293 Scrip Symbol: SURAKSHA Dear
Slide 2: Q2 & H1 FY25 Investor Presentation
Suraksha Diagnostic Limited Q2 & H1 FY25 Investor Presentation
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation and the accompanying slides (the “Presentation”), which have been prepared by Suraksha Diagnostic Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe
Slide 4: Company Overview
Clinic & Diagnostics
Slide 5: Business at a Glance
Business at a Glance as of 30th September, 2024 9 0.61 Mn 3.29 Mn ₹ 2,099 Labs Patients Served Tests Performed Revenue per patient (H1 FY25) (H1 FY25) (H1 FY25) 51 276 26 ₹ 761 Diagnostic Centres Doctors CT Machines EBITDA per patient (H1 FY25) 178 3 13 ₹ 142 Mn Collection Centres NABL accredited la
Slide 6: Evolution to the Largest Integrated Diagnostic Chain in East India
Evolution to the Largest Integrated Diagnostic Chain in East India 1992 2010 2016 2024 Built fully comprehensive 5 centres Received second round of 51 centres diagnostic centre, under funding from OrbiMed brand ‘Suraksha’ Exit of Lighthouse Funds 9 Labs 2007 2013 25 centres 2020 IPO and listing on B
Slide 7: Deeply Entrenched in the vital Geography of West Bengal
Deeply Entrenched in the vital Geography of West Bengal 2 2 47 Centers in West Bengal No. of centres >10 centres 1 3 centres 2 centres 1 centres Bihar Assam • 4th most populous state in India • Fragmented market with low penetration of Population Legend Meghalaya chained diagnostic centres West Beng
Slide 8: Hub & Spoke Operating Model
Hub & Spoke Operating Model Modalities Offered Key Stats # of doctors & Area Hub Centres employees / centre Large MRI CT Scan USG Gastroenterology Neurology Pathology Centres 30-40 5,000 – 8,000 sq. ft X-Ray Cardiology Mammo OPG Dexa Medium 20-25 2,500 – 5,000 sq. ft Centres CT-Scan USG X-Ray Neurol
Slide 9: …..with Demonstrated Success
…..with Demonstrated Success Demonstrated success in Kolkata region with significant potential Operational Network(1) for future growth2 1 Central Lab (equipped to conduct all pathology 8 Satellite Labs 13 Hub Centres sample collection, basic and advanced radiology tests) (co-located with hub centre
Slide 10: Well-established Operational Network - Greater Economies of Scale
Well-established Operational Network - Greater Economies of Scale Report Flow Patient P.A.C.S RAD IMAGE (Software) (Scrutiny) (Report) Image/Report Flow Image Flow Patients Flow #13 #1 Hub Centre Flagship Reference Lab Doctor #8 #38 Spoke Centre SATELLITE LAB Polyclinic Doctor Customers Samples Coll
Slide 11: Customer Convenience through Value Added Services
Customer Convenience through Value Added Services Customer Centric Approach Value Added Services enhancing customer experience and convenience Home Polyclinic Online SMS Alerts Collection Chambers Bookings Allows samples to be Customers receive an Polyclinic chambers Customers can book collected fro
Slide 12: Dynamic and Diverse Management Team to deliver the Next Phase of Growth
Dynamic and Diverse Management Team to deliver the Next Phase of Growth Dr. Somnath Chatterjee Ritu Mittal Chairman of the Board and Joint Managing Director Joint Managing Director & Chief Executive Officer Associated with Suraksha since incorporation; 32+ years of experience Associated with Suraksh
Slide 13: Strategy and Outlook
Strategy and Outlook 12
Slide 14: Leveraging Strengths to drive Competitive Advantage
Leveraging Strengths to drive Competitive Advantage Largest diagnostic chain with a dominant position in Eastern India; well-positioned to benefit from the 01 high-growth opportunity for organized diagnostic chains in the fragmented markets in Eastern and North- Eastern India Integrated diagnostics
Slide 15: Key Differentiating Factors
Key Differentiating Factors Polyclinic Diversified in terms of revenue from services 126 750+ Chambers1 Doctors1 Omnichannel medical consultation services via online and offline modes through diagnostic centres which house the polyclinic chambers Model of integrated pathology, radiology and medical
Slide 16: Strategies to Drive Future Growth
Strategies to Drive Future Growth Expand in adjacent Increase share of Engage in Business- Supplement organic Leverage technology Strengthen position geographies of medical consultation to-Business (“B2B”) growth with selective to elevate customer in core geography Eastern and North- services at dia
Slide 17: Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets
Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets Expand in adjacent geographies of Eastern and Consolidate leading position in the core geography by Supplement organic growth with selective acquisitions North-Eastern India Open additional diagnostic centres and increase Ide
Slide 18: Industry Overview
Industry Overview 17
Slide 19: Industry: Poised for High Growth; Shifting Towards Organized Market
Industry: Poised for High Growth; Shifting Towards Organized Market Diagnostic market expected to grow at 10-12% CAGR between FY24 & FY28 Organized players gaining market share from standalone labs at a steady rate CAGR 10-12% 1,275-1,375 36-40% 36-40% 860-870 13- 20- 17% 24% 45-49% 35-39% FY24E FY2
Slide 20: Eastern India - An Underserved Market with Premium Pricing
Eastern India - An “Underserved” Market with Premium Pricing Disparity in access to accredited testing services in Region has the lowest number of NABH East India(1) market also offers premium Eastern(1) India relative to population needs accredited hospitals pricing for diagnostic tests 430 80-90 8
Slide 21: Company Financials
Company Financials 20
Slide 22: Consolidated Financial Performance – Q2 FY25
Consolidated Financial Performance – Q2 FY25 Total Income (INR Mn) EBITDA (INR Mn) PAT (INR Mn) 35.6% 35.8% 36.7% 13.9% 12.6% 15.2% +12% +15% +22% 681 245 102 606 618 214 217 83 77 Q2 FY24 Q1FY25 Q2 FY25 Q2 FY24 Q1FY25 Q2 FY25 Q2 FY24 Q1FY25 Q2 FY25 21
Slide 23: Consolidated Financial Performance – H1 FY25
Consolidated Financial Performance – H1 FY25 Total Income (₹ Mn) EBITDA (₹ Mn) PAT (₹ Mn) 33.1% 36.3% 11.0% 14.0% +15% +25% +45% 1,299 462 178 1,134 370 123 H1 FY24 H1 FY25 H1 FY24 H1 FY25 H1FY24 H1 FY25 22
Slide 24: Profit & Loss Statement (Consolidated)
Profit & Loss Statement (Consolidated) Particulars (INR Mn) Q2 FY25 Q2 FY24 Y-o-Y Q1 FY25 Q-o-Q H1 FY25 H1 FY24 Y-o-Y Revenue from Operations 667.54 600.49 607.32 1,274.85 1,117.00 Other Income 13.13 5.55 11.17 24.30 17.23 Total Income 680.67 606.05 12.3% 618.48 10.1% 1,299.15 1,134.23 14.5% Cost of
Slide 25: Consolidated Balance Sheet (1/2)
Consolidated Balance Sheet (1/2) Particulars (INR Mn) H1 FY25 FY24 ASSETS Non ‐ Current Assets Property, plant and equipment 1,385.46 1,350.50 Capital work‐in‐progress 47.54 13.13 Right of use assets 709.83 754.09 Other Intangible assets 12.31 10.76 Intangible Assets under development 4.96 - Financi
Slide 26: Consolidated Balance Sheet (2/2)
Consolidated Balance Sheet (2/2) Particulars (INR Mn) H1 FY25 FY 2024 Equity (a) Equity share capital 86.25 69.00 (b) Instruments entirely equity in nature 16.29 16.29 (c) Other equity 1,871.68 1708.80 Equity attributable to equity holders of the parent 1,974.22 1,794.08 Non‐controlling interests -6
Slide 27: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (INR Mn) H1 FY25 H1 FY24 Cash Flow from Operating Activities Profit before Tax 241.46 160.02 Adjustment for Non-Operating Items 209.53 202.70 Operating Profit before Working Capital Changes 450.99 362.71 Changes in Working Capital -35.33 -8.14 Cash Genera
Slide 28: Key Awards & Recognition
Key Awards & Recognition 2017 Best quality in 2019 Best customer service 2021 Business leader service delivery(1) in healthcare(1) of the year(2) Certificate of excellence Outstanding 2021 Awards & certificate 2022 2023 in exemplary trust & diagnostic chain of of excellence(3) commitment towards eas
Slide 29: Thank You
For further information, please contact: Company : Suraksha Diagnostic Limited CIN: U85110WB2005PLC102265 investors@surakshanet.com Email: investors@surakshanet.com Thank You Investor Relations Advisors : Mr. Ashish Tendulkar +91 98209 53312 ashish.tendulkar@linkintime.co.in Ms. Pooja Swami +91 9860